Are you medically eligible?
FDA-approved indications for GLP-1 chronic weight management (Wegovy, Zepbound, Foundayo, oral Wegovy) require either: BMI ≥30 (obesity), OR BMI ≥27 with at least one weight-related comorbidity.
Qualifying comorbidities: hypertension, type 2 diabetes, dyslipidemia, sleep apnea, established cardiovascular disease, non-alcoholic fatty liver disease (NAFLD/MASH), or PCOS. Your prescriber will assess whether your condition meets the threshold.
Three pathways to a prescription
Pathway 1 — telehealth (fastest). Ro, Hims & Hers, Sequence, MEDVi, and Push Health all offer online intake → physician review → e-prescription in 24-72 hours if you meet eligibility. Best for self-pay or commercial insurance patients without complex medical history.
Pathway 2 — your primary care provider. Slower (2-4 week wait for many PCPs) but optimal if your insurance requires PCP coordination or if you have multiple comorbidities that need ongoing management.
Pathway 3 — endocrinologist. Reserved for complex cases: type 1 diabetes, thyroid disorders, MEN-2 family history (boxed warning), or prior intolerance to lower-dose GLP-1s.
What happens at the telehealth consultation
Most telehealth GLP-1 consultations are asynchronous: you fill out a 5-10 minute intake form (weight, height, medical history, current medications, allergies), upload a photo ID, and submit. A licensed physician in your state reviews and either approves, requests labs, or declines.
If approved, prescription is sent to your home pharmacy (or the provider's contracted pharmacy) within 24-72 hours. First shipment typically arrives in 5-7 business days.
What labs are typically ordered
Most telehealth providers do NOT require labs before initial prescription if your medical history is uncomplicated. If labs are requested, the standard panel includes: HbA1c (diabetes screen), comprehensive metabolic panel (kidney/liver function), and lipid panel (cardiovascular risk baseline).
Calcitonin levels are NOT routinely required despite the GLP-1 thyroid boxed warning — current guidance is that family history screening (MEN-2, medullary thyroid cancer) is sufficient.
Maximize your approval odds
1. Be honest about your BMI and conditions. Telehealth providers verify weight at re-orders; misrepresenting can cause discontinuation.
2. Document your comorbidity. If you're BMI 27-30, an existing dx code for hypertension/dyslipidemia/sleep apnea on file dramatically helps.
3. If self-pay, ask about brand-name savings cards. Novo (Wegovy) and Lilly (Zepbound, Foundayo) both offer commercially-insured patient assistance that drops list price ~60%.
Frequently asked questions
- How fast can I get a GLP-1 prescription via telehealth?
- Most providers approve eligible patients within 24-72 hours and ship medication in 5-7 business days. Fastest end-to-end (intake → arrival) is typically 7-10 days.
- What BMI is required for Ozempic or Wegovy?
- BMI ≥30 alone qualifies. BMI 27-30 qualifies WITH at least one weight-related condition (hypertension, sleep apnea, dyslipidemia, diabetes, or cardiovascular disease).
- Do I need lab work before getting a GLP-1?
- Not always. Most telehealth providers prescribe without labs for uncomplicated patients. If you have diabetes, complex medical history, or your provider requires it, expect HbA1c + metabolic panel + lipid panel.
- Can I get a GLP-1 prescription without seeing a doctor in person?
- Yes — telehealth providers like Ro, Hims, and Sequence handle the entire process online, including consultation and prescription. A licensed physician in your state reviews your case.
- What if I get denied?
- Common reasons: BMI below threshold, missing comorbidity documentation, contraindication (MEN-2 family history, history of medullary thyroid cancer). Options: try a different provider, get a documented comorbidity dx from your PCP, or wait and re-apply.
Disclosure: Glpverdict is affiliate-funded but editorially independent. Some links above are sponsored — we may earn a commission if you sign up with a partner provider. This does not affect our editorial rankings or medical review.
